Related Experiment Videos

Hamster pancreatic beta cell lines with altered sensitivity towards apoptotic signalling by phosphatase inhibitors

A Krautheim1, P Brechlin, K Becker

  • 1Institute of Pharmacology and Toxicology, University of Gottingen, D-37075 Gottingen, Germany.

Insights

Pancreatic beta cells resistant to okadaic acid developed multidrug resistance, likely due to enhanced pgp1 gene expression. This resistance did not extend to other phosphatase inhibitors like cantharidic acid.

Area of Science:

  • Cell Biology
  • Biochemistry
  • Pharmacology

Background:

  • Okadaic acid, a serine/threonine phosphatase inhibitor, induces apoptotic cell death in pancreatic beta cells.
  • Development of resistance to okadaic acid in HIT cells (HIT100R) allows proliferation at previously lethal concentrations.

Purpose of the Study:

  • To characterize the apoptotic events triggered by okadaic acid in parental HIT and resistant HIT100R cells.
  • To investigate the mechanism of resistance to okadaic acid and potential cross-resistance with other phosphatase inhibitors.

Main Methods:

  • Induction of apoptosis using okadaic acid and cantharidic acid.
  • Biochemical analysis of apoptosis markers (cytochrome c release, caspase-3 activity).
  • Assessment of phosphatase activity and drug accumulation.
  • Analysis of multidrug resistance gene expression (pgp1, pgp2).

Main Results:

  • Apoptosis induction by okadaic acid required higher concentrations in HIT100R cells compared to HIT cells.
  • No cross-resistance was observed with cantharidic acid, indicating distinct resistance mechanisms.
  • HIT100R cells exhibited the multidrug resistance phenotype, linked to enhanced pgp1 gene expression.
  • Total phosphatase activity and sensitivity to okadaic acid were similar in both cell lines.

Conclusions:

  • HIT100R cells acquired resistance to okadaic acid through the development of multidrug resistance, specifically involving pgp1.
  • The resistance mechanism is specific to okadaic acid and does not confer cross-resistance to structurally different phosphatase inhibitors.
  • Understanding these resistance mechanisms is crucial for developing targeted therapies for pancreatic beta cell protection or drug development.

Related Concept Videos